Confirmed A1c reduction under real world conditions after once daily administration of Lixisenatide to basal insulin

Trial Profile

Confirmed A1c reduction under real world conditions after once daily administration of Lixisenatide to basal insulin

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs Lixisenatide (Primary) ; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top